Omics-based nanomedicine: The future of personalized oncology

Cancer Letters

Volumn 352, Issue 1, 2014, Pages 126-136

  Rosenblum, Daniel ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Nanomedicine; Omics; Personalized medicine; RNAi; Theranostics

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; CRIZOTINIB; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FERUCARBOTRAN; GADOLINIUM; GEMCITABINE; INIPARIB; LIPOSOME; MANGANESE; NANOCARRIER; PACLITAXEL; PANITUMUMAB; PEMETREXED; SGT 53; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DNA METHYLATION; DNA REPAIR; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG TOXICITY; ECHOGRAPHY; FLUORESCENCE IMAGING; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENOMICS; HUMAN; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MOLECULAR IMAGING; MULTIPLE MYELOMA; NANOMEDICINE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM;

NANOMEDICINE; OMICS; PERSONALIZED MEDICINE; RNAI; THERANOSTICS;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; NEOPLASMS;

EID: 84906064921     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.029     Document Type: Review

References (105)

1. Donna J.X.L., Hoyert L. Deaths: preliminary data for 2011. Natl. Vital Statist. Rep. 2012, 61.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics 2013. CA: Cancer J. Clin. 2013, 63:11-30.
3. Diou O., Tsapis N., Fattal E. Targeted nanotheranostics for personalized cancer therapy. Exp. Opin. Drug Deliv. 2012, 9:1475-1487.
4. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5:845-856.
5. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
6. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
7. Daka A., Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 2012, 64:1508-1521.
8. Elinav E., Peer D. Harnessing nanomedicine for mucosal theranostics - a silver bullet at last?. ACS Nano 2013, 7:2883-2890.
9. Venditto V.J., Szoka F.C. Cancer nanomedicines: so many papers and so few drugs!. Adv. Drug Deliv. Rev. 2013, 65:80-88.
10. Goldenberg M.M. Pharmaceutical approval update. P & T: Peer - Rev. J. Formulary Manage. 2012, 37:668-708.
11. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., Paz-Ares L., Cho D.C., Infante J.R., Alsina M., Gounder M.M., Falzone R., Harrop J., White A.C., Toudjarska I., Bumcrot D., Meyers R.E., Hinkle G., Svrzikapa N., Hutabarat R.M., Clausen V.A., Cehelsky J., Nochur S.V., Gamba-Vitalo C., Vaishnaw A.K., Sah D.W., Gollob J.A., Burris H.A. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discovery 2013, 3:406-417.
12. Kato K., Chin K., Yoshikawa T., Yamaguchi K., Tsuji Y., Esaki T., Sakai K., Kimura M., Hamaguchi T., Shimada Y., Matsumura Y., Ikeda R. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 2012, 30:1621-1627.
13. Mura S., Couvreur P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 2012, 64:1394-1416.
14. Hamburg M.A., Collins F.S. The path to personalized medicine. New Engl. J. Med. 2010, 363:301-304.
15. Roberts N.J., Vogelstein J.T., Parmigiani G., Kinzler K.W., Vogelstein B., Velculescu V.E. The predictive capacity of personal genome sequencing. Sci. Trans. Med. 2012, 4:133ra158.
16. Gonzalez de Castro D., Clarke P.A., Al-Lazikani B., Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin. Pharmacol. Ther. 2013, 93:252-259.
17. Reynolds J.G., Geretti E., Hendriks B.S., Lee H., Leonard S.C., Klinz S.G., Noble C.O., Lucker P.B., Zandstra P.W., Drummond D.C., Olivier K.J., Nielsen U.B., Niyikiza C., Agresta S.V., Wickham T.J. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol. Appl. Pharmacol. 2012, 262:1-10.
18. Silvestri A., Pin E., Huijbers A., Pellicani R., Parasido E.M., Pierobon M., Petricoin E., Liotta L., Belluco C. Individualized therapy for metastatic colorectal cancer. J. Internal Med. 2013, 274:1-24.
19. National Cancer Institute. Bethesda, SEER Cancer Statistics Review, 1975-2005. , 2008. http://seer.cancer.gov/csr/1975_2005/.
20. Vecchione L., Jacob B., Normanno N., Ciardiello F., Tejpar S. EGFR-targeted therapy. Exp. Cell. Res. 2011, 317:2765-2771.
21. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
22. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl. J. Med. 2008, 359:1757-1765.
23. Carey L.A., Sharpless N.E. PARP and cancer-if it is broke, do not fix it. New Engl. J. Med. 2011, 364:277-279.
24. Sudo T. Molecular-targeted therapies for ovarian cancer: prospects for the future. Int. J. Clin. Oncol. 2012, 17:424-429.
25. Martin S.A., Lord C.J., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Gen. Develop. 2008, 18:80-86.
26. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Koo I.C., Sherman B.M., Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New Engl. J. Med. 2011, 364:205-214.
27. Hallberg B., Palmer R.H. ALK and NSCLC targeted therapy with ALK inhibitors. F1000 Med. Rep. 2011, 3:21.
28. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
29. Casaluce F., Sgambato A., Maione P., Rossi A., Ferrara C., Napolitano A., Palazzolo G., Ciardiello F., Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncol. 2013, 8:55-67.
30. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 2009, 21:215-223.
31. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., Rossig C., Russell H.V., Diouf O., Liu E., Liu H., Wu M.F., Gee A.P., Mei Z., Rooney C.M., Heslop H.E., Brenner M.K. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
32. Cartellieri M., Bachmann M., Feldmann A., Bippes C., Stamova S., Wehner R., Temme A., Schmitz M. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010, 2010:956304.
33. Davila M.L., Brentjens R., Wang X.Y., Riviere I., Sadelain M. How do CARs work? Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012, 1:1577-1583.
34. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., Yang J.C., Kammula U.S., Devillier L., Carpenter R., Nathan D.A., Morgan R.A., Laurencot C., Rosenberg S.A. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
35. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
36. Ciceri F., Bonini C., Stanghellini M.T., Bondanza A., Traversari C., Salomoni M., Turchetto L., Colombi S., Bernardi M., Peccatori J., Pescarollo A., Servida P., Magnani Z., Perna S.K., Valtolina V., Crippa F., Callegaro L., Spoldi E., Crocchiolo R., Fleischhauer K., Ponzoni M., Vago L., Rossini S., Santoro A., Todisco E., Apperley J., Olavarria E., Slavin S., Weissinger E.M., Ganser A., Stadler M., Yannaki E., Fassas A., Anagnostopoulos A., Bregni M., Stampino C.G., Bruzzi P., Bordignon C. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009, 10:489-500.
37. Pareek C.S., Smoczynski R., Tretyn A. Sequencing technologies and genome sequencing. J. Appl. Gen. 2011, 52:413-435.
38. Shyr D., Liu Q. Next generation sequencing in cancer research and clinical application. Biol. Proced. Online 2013, 15:4.
39. N.Cancer Genome Atlas Comprehensive molecular portraits of human breast tumors. Nature 2012, 490:61-70.
40. N.Cancer Genome Atlas Research Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
41. N.Cancer Genome Atlas Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
42. N.Cancer Genome Atlas Research Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
43. Totoki Y., Tatsuno K., Yamamoto S., Arai Y., Hosoda F., Ishikawa S., Tsutsumi S., Sonoda K., Totsuka H., Shirakihara T., Sakamoto H., Wang L., Ojima H., Shimada K., Kosuge T., Okusaka T., Kato K., Kusuda J., Yoshida T., Aburatani H., Shibata T. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Gen. 2011, 43:464-469.
44. Ma Q., Lu A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 2011, 63:437-459.
45. Ehmann M., Felix K., Hartmann D., Schnolzer M., Nees M., Vorderwulbecke S., Bogumil R., Buchler M.W., Friess H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 34:205-214.
46. Petricoin E.F., Zoon K.C., Kohn E.C., Barrett J.C., Liotta L.A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 2002, 1:683-695.
47. Honda K., Ono M., Shitashige M., Masuda M., Kamita M., Miura N., Yamada T. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn. J. Clin. Oncol. 2013, 43:103-109.
48. Cho Y.T., Su H., Huang T.L., Chen H.C., Wu W.J., Wu P.C., Wu D.C., Shiea J. Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry for clinical diagnosis. Clin. Chimica Acta Int. J. Clin. Chem. 2013, 415:266-275.
49. Murakoshi Y., Honda K., Sasazuki S., Ono M., Negishi A., Matsubara J., Sakuma T., Kuwabara H., Nakamori S., Sata N., Nagai H., Ioka T., Okusaka T., Kosuge T., Shimahara M., Yasunami Y., Ino Y., Tsuchida A., Aoki T., Tsugane S., Yamada T. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. 2011, 102:630-638.
50. Chen R., Mias G.I., Li-Pook-Than J., Jiang L., Lam H.Y., Chen R., Miriami E., Karczewski K.J., Hariharan M., Dewey F.E., Cheng Y., Clark M.J., Im H., Habegger L., Balasubramanian S., O'Huallachain M., Dudley J.T., Hillenmeyer S., Haraksingh R., Sharon D., Euskirchen G., Lacroute P., Bettinger K., Boyle A.P., Kasowski M., Grubert F., Seki S., Garcia M., Whirl-Carrillo M., Gallardo M., Blasco M.A., Greenberg P.L., Snyder P., Klein T.E., Altman R.B., Butte A.J., Ashley E.A., Gerstein M., Nadeau K.C., Tang H., Snyder M. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293-1307.
51. Schubert C. Single-cell analysis: the deepest differences. Nature 2011, 480:133-137.
52. Metzker M.L. Applications of next-generation sequencing sequencing technologies - the next generation. Nat. Rev. Genet 2010, 11:31-46.
53. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Bba - Rev. Cancer 1805, 2010:105-117.
54. Wang D., Bodovitz S. Single cell analysis: the new frontier in 'omics'. Trends Biotechnol. 2010, 28:281-290.
55. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., Muthuswamy L., Krasnitz A., McCombie W.R., Hicks J., Wigler M. Tumor evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
56. Hou Y., Song L.T., Zhu P., Zhang B., Tao Y., Xu X., Li F.Q., Wu K., Liang J., Shao D., Wu H.J., Ye X.F., Ye C., Wu R.H., Jian M., Chen Y., Xie W., Zhang R.R., Chen L., Liu X., Yao X.T., Zheng H.C., Yu C., Li Q.B., Gong Z.L., Mao M., Yang X., Yang L., Li J.X., Wang W., Lu Z.H., Gu N., Laurie G., Bolund L., Kristiansen K., Wang J., Yang H.M., Li Y.R., Zhang X.Q., Wang J. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012, 148:873-885.
57. O'Flaherty J.D., Gray S., Richard D., Fennell D., O'Leary J.J., Blackhall F.H., O'Byrne K.J. Circulating tumor cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012, 76:19-25.
58. Lien K.Y., Chuang Y.H., Hung L.Y., Hsu K.F., Lai W.W., Ho C.L., Chou C.Y., Lee G.B. Rapid isolation and detection of cancer cells by utilizing integrated microfluidic systems. Lab Chip 2010, 10:2875-2886.
59. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J. Controlled Release: Official J. Controlled Release Soc. 2012, 160:117-134.
60. Barenholz Y.C., Peer D. Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chem. Phys. Lipids 2012, 165:363-364.
61. Barenholz Y., Peer D. Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. J. Controlled Release: Official J. Controlled Release Soc. 2012, 160:115-116.
62. Peer D. A daunting task: manipulating leukocyte function with RNAi. Immunol. Rev. 2013, 253:185-197.
63. Silverman J.A., Deitcher S.R. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 2013, 71:555-564.
64. Weiss G.J., Chao J., Neidhart J.D., Ramanathan R.K., Bassett D., Neidhart J.A., Choi C.H., Chow W., Chung V., Forman S.J., Garmey E., Hwang J., Kalinoski D.L., Koczywas M., Longmate J., Melton R.J., Morgan R., Oliver J., Peterkin J.J., Ryan J.L., Schluep T., Synold T.W., Twardowski P., Davis M.E., Yen Y. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 2013.
65. Perche F., Torchilin V.P. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Deliv. 2013, 2013:705265.
66. Senzer N., Nemunaitis J., Nemunaitis D., Bedell C., Edelman G., Barve M., Nunan R., Pirollo K.F., Rait A., Chang E.H. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:1096-1103.
67. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J. I.I.I.C.T.c. cancer research campaign phase, hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
68. Peer D. Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. J. Controlled Release: Official J. Controlled Release Soc. 2010, 148:63-68.
69. Tuscano J.M., Martin S.M., Ma Y., Zamboni W., O'Donnell R.T. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2010, 16:2760-2768.
70. Saad M., Garbuzenko O.B., Ber E., Chandna P., Khandare J.J., Pozharov V.P., Minko T. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J. Controlled Release: Official J. Controlled Release Soc. 2008, 130:107-114.
71. Yang T., Choi M.K., Cui F.D., Lee S.J., Chung S.J., Shim C.K., Kim D.D. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm. Res. 2007, 24:2402-2411.
72. Tong S., Cradick T.J., Ma Y., Dai Z., Bao G. Engineering imaging probes and molecular machines for nanomedicine. Sci. China Life Sci. 2012, 55:843-861.
73. Chen W., Cormode D.P., Fayad Z.A., Mulder W.J.M. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wires Nanomed. Nanobi. 2011, 3:146-161.
74. Liu F.J., Laurent S., Fattahi H., Elst L.V., Muller R.N. Superparamagnetic nanosystems based on iron oxide nanoparticles for biomedical imaging. Nanomed. UK 2011, 6:519-528.
75. Hahn M.A., Singh A.K., Sharma P., Brown S.C., Moudgil B.M. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal. Bioanal. Chem. 2011, 399:3-27.
76. Cai W.B., Chen X.Y. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007, 3:1840-1854.
77. Cheon J., Lee J.H. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc. Chem. Res. 2008, 41:1630-1640.
78. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anti-cancer Agents Med. Chem. 2006, 6:407-428.
79. Ross R.W., Zietman A.L., Xie W., Coen J.J., Dahl D.M., Shipley W.U., Kaufman D.S., Islam T., Guimaraes A.R., Weissleder R., Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imaging 2009, 33:301-305.
80. Sawant R.R., Jhaveri A.M., Torchilin V.P. Immunomicelles for advancing personalized therapy. Adv. Drug Deliv. Rev. 2012, 64:1436-1446.
81. Ding H., Yong K.T., Law W.C., Roy I., Hu R., Wu F., Zhao W., Huang K., Erogbogbo F., Bergey E.J., Prasad P.N. Non-invasive tumor detection in small animals using novel functional Pluronic nanomicelles conjugated with anti-mesothelin antibody. Nanoscale 2011, 3:1813-1822.
82. Martina M.S., Fortin J.P., Menager C., Clement O., Barratt G., Grabielle-Madelmont C., Gazeau F., Cabuil V., Lesieur S. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J. Am. Chem. Soc. 2005, 127:10676-10685.
83. Erten A., Wrasidlo W., Scadeng M., Esener S., Hoffman R.M., Bouvet M., Makale M. Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomed. UK 2010, 6:797-807.
84. Tai L.A., Tsai P.J., Wang Y.C., Wang Y.J., Lo L.W., Yang C.S. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology 2009, 20:135101.
85. Grange C., Geninatti-Crich S., Esposito G., Alberti D., Tei L., Bussolati B., Aime S., Camussi G. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res. 2010, 70:2180-2190.
86. Cittadino E., Ferraretto M., Torres E., Maiocchi A., Crielaard B.J., Lammers T., Storm G., Aime S., Terreno E. MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. Euro. J. Pharm. Sci.: Official J. Euro. Federation Pharm. Sci. 2012, 45:436-441.
87. Nurunnabi M., Cho K.J., Choi J.S., Huh K.M., Lee Y.K. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010, 31:5436-5444.
88. Peer D., Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther. 2011, 18:1127-1133.
89. Amarzguioui M., Rossi J.J., Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 2005, 579:5974-5981.
90. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
91. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucl. Acids Res. 2006, 34:322-333.
92. Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A., Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Co. 2002, 296:1000-1004.
93. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Rohl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
94. Dorn G., Patel S., Wotherspoon G., Hemmings-Mieszczak M., Barclay J., Natt F.J.C., Martin P., Bevan S., Fox A., Ganju P., Wishart W., Hall J. siRNA relieves chronic neuropathic pain. Nucl. Acids Res. 2004, 32.
95. Shen J., Samul R., Silva R.L., Akiyama H., Liu H., Saishin Y., Hackett S.F., Zinnen S., Kossen K., Fosnaugh K., Vargeese C., Gomez A., Bouhana K., Aitchison R., Pavco P., Campochiaro P.A. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006, 13:225-234.
96. Miller V.M., Xia H.B., Marrs G.L., Gouvion C.M., Lee G., Davidson B.L., Paulson H.L. Allele-specific silencing of dominant disease genes. P. Natl. Acad. Sci. USA 2003, 100:7195-7200.
97. Moghimi S.M., Peer D., Langer R. Reshaping the future of nanopharmaceuticals: Ad iudicium. ACS Nano 2011, 5:8454-8458.
98. Wu S., Singh R.K. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr. Mol. Med. 2011, 11:553-563.
99. Chen Y.C., Zhu X.D., Zhang X.J., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18:1650-1656.
100. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
101. Zhang M., Garbuzenko O.B., Reuhl K.R., Rodriguez-Rodriguez L., Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine (Lond) 2012, 7:185-197.
102. Kormann M.S., Hasenpusch G., Aneja M.K., Nica G., Flemmer A.W., Herber-Jonat S., Huppmann M., Mays L.E., Illenyi M., Schams A., Griese M., Bittmann I., Handgretinger R., Hartl D., Rosenecker J., Rudolph C. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011, 29:154-157.
103. Wang Y., Su H.H., Yang Y., Hu Y., Zhang L., Blancafort P., Huang L. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:358-367.
104. Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 2012, 64:1738-1748.
105. Ratner M. Pfizer reaches out to academia-again. Nat. Biotechnol. 2011, 29:3-4.